Морфофункциональное значение простатического специфического антигена и высокомолекулярного цитокератина при заболеваниях предстательной железы

Список литературы

1. Аксель Е.М.// Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России //"0нкоурология", 2005, № 1, http://netoncology.ru/view.php7icH859.
2. Аничков Н.М., Плотникова Н. А. Архив патологии.-2001.-т.63.-№ 5.-с.44−50.
3. Воробьев А. В., // Обзор важнейших событий в онкоурологии// Пркт. Онк. 2005, Т 6, No 1, с.55−64.
4. Воробьев А. В.// Скрининг мужского населения, стандартное обследование пациентов, классификация рака предстательной железы// Пркт. Онк., 2001, № 2 (6) (июнь).
5. Гундорова Л.В.//Дифференциальная диагностика гиперпластических и опухолевых процессов предстательной железы (иммуногистохимичесое и плоидометрическое исследование).// Диссерт.д.м.н. Москва, 2005
6. Каприн А.Д., Ананьев А. П., Амосов Ф. Р., Гафанов Р.А.//Диагностика рака предстательной железы//Вопросы онкологии.- 1999- т.45-№ 1: с.20−5.
7. Карселадзе А.И., Рытин И. Э., Будунова И.В.// Иммуногистохимическое исследование простатического специфического антигена в раке предстательной железы//Архив патологии.-2004.-т.66.-№ 2.-с.З-7.
8. Ковыршина Л.А. дисс. к.м.н //Клинико-морфологическая оценка уровней ПСА при заболеваниях предстательной железы// С-Петербург, 2002.
9. Любимова Н.В., Кушлинский Н. Е., Стогова Э. В. и др. //Клиническое значение общего и свободного простатического специфического антигена при раке предстательной железы // Клин. лаб. диагностика. 1998. — № 2. -с. 6−9.
10. Медведев В.Л., Мационис А. Э., Медведева Л.А.// Клиническое значение гистологических типов рака предстательной железы// Урология.- 2003.-№ 6.-с. 10−14.
11. Переверзев О.С., Коган М. Л. // Рак простаты // X.: Факт. 2004. 231 с.
12. Петров С.Б., Харченко П.В.// диагностика локализованного рака предстательной железы// Урология. -2005.-№ 1.-е. 19−22.
13. Пожарисский К.М., Воробьев А. В. // Патоморфологическая характеристика и особенности карциномы предстательной железы. Значение простатической интраэпителиальной неоплазии// Практическая Онкология, — 2001.-т. .-№ 2(июнь).-с. .
14. Романенко А.В.// гиперплазия предстательной железы, в кн «Руководство по иммуногистохимической диагностике опухолей человека» под ред. С. В. Петрова и Н.Т. Райхлина- 3-е изд., перераб и доп.- Казань, 2004- с.143−149.
15. Самсонов В.А. //Опухоли предстательной железы в кн. «Патолого-анатомическая диагностика опухолей» т.2 /под ред. Н. А. Краевского, А. В. Смольянникова, Д. С. Саркисова. 4-е изд., перераб и доп.- М.: Медицина, 1993, с.338−348.
16. Ткачева Г. А., Балаболкин М. И., Ларичева И. П. Радиохимические методы исследованиям., «Медицина», 1983.
17. Abate Shen С., Shen М.М. //Molecular genetics of prostate cancer// Genes Dev. 2000 — v. 14. — p. 2410−243.
18. Agus D., Cordon-Cardo C., Fox W., Drobnjak M., Koff A., Golde D., Scher H.// Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence.// J. Natl. Cancer Inst., 1999, 91-p.l 869−1876.
19. Altay В., Kefi A., Nazli O., Killi R., Semerci В., Akar I.//Comparison of Gleason scores from sextant prostate biopsies and radical prostatectomy specimens.// Urol Int., 2001, v. 67−1- p. 14−8.
20. Amayo A., Obara W.//Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.// East Afr Med J., 2004-v.81-l (Jan) — p 22−6.
21. Amin M.B., Schultz D.S., Zarbo R.J., Kubus J., Shaheen C.//Computerized static DNA ploidy analysis of prostatic intraepithelial neoplasia.//Arch Pathol Lab Med., 1993, v. l 17−8 (Aug) — p.794−8.
22. Amin M.B., Schultz D.S., Zarbo R.J.// Analysis of cribriform morphology in prostatic neoplasia using antibody to high-molecular-weight cytokeratins.//Arch Pathol Lab Med., 1994, v. l 18−3 (Mar) — p.260−4.
23. Amundson S.A., Myers T.G., Scudiero D., Kitada S., Reed J.C., Fornace A.J. Jr.// An informatics approach identifying markers of chemosensitivity in human cancer cell lines.//Cancer Res., 2000, 1−60−21 (Nov) — p.6101−10.
24. Armitage T.G., Cooper E.H.// The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.//Brit. J. Urol., 1988, v. 62- p. 584.
25. Ayala A. G., Troncoso P., Ro J. Y. // Pathology in Incipient Neoplasia / Eds D. E. Henson, J. Albores-Saavedra. Philadelphia, 1993, p. 363−383.
26. Baisden B.L., Kahane H., Epstein J. L //Perineural invasion, mucinous fibroplasia and glomerulations: diagnostic features on prostate needle biopsy// Am J Surg Pathol., 1999, v.23−8 (Aug)-p. 918−24.
27. Barnes DM.//Cyclin D1 in mammary carcinoma.// J Pathol., 1997,181- p.267−69.
28. Bauer J.J., Connelly R.R., Seterhenn I.A., et al.,// Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk for prostate carcinoma recurrence after radical prostatectomy.// Cancer, 1997, v. 79 5- p. 952−962.
29. Bjork Т., Ljungberg В., Piironen T., et al., // Rapid exponential elimination of free prostate specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha-1-antichymotrypsin from serum.// Urol., 1998, v. 51−1-p. 57−62.
30. Bobrow M., et al. //Catalyzed reporter deposition, a novel method of signal amplification: Application to immunoassays.//J.Immunol.Meth., 1989-p. 125 279.
31. Bocking A, Kiehn J, Heinzel-Wach M. //Combined histologic grading of prostatic carcinoma.//Cancer., 1982, v.15−50−2- (Jul) — p.288−94.
32. Bonkhoff H, Remberger KM Diagnostic criteria and differential diagnosis of prostatic intraepithelial neoplasia// Pathologe., 1998, v.19−1 (Jan) — p.33−41.
33. Bostwick D. G., Algaba F., Amin N. B. et al. //Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate.//Am. J. Surg. Pathol., 1994,-v. 18- p. 1069−1070.
34. Bostwick D.G., Qian J.//High-grade prostatic intraepithelial neoplasia.// Mod Pathol., 2004-v.l7−3(Mar.) — p.360−79.
35. Bostwick D.G.//PSA current role in diagnostic pathology of the prostate.// J. Clin. Pathol., 1994, v. 102- p.531−537.
36. Brawer M.K., Large P.H. // PSA: its role in early detection, staging and monitoring of prostatic carcinoma.// Endourol., 1989, v. 3- p. 227.
37. Cadeddu J. A., Elashry O.M., Snyder O., et al.,// Effect of laparoscopic pelvic lymph node dissection on the natural history of D1 (T1−3, N1−3, MO) prostate cancer.// Urol., 1997, v. 50- 3- p 391−394.
38. Cadeddu J.A., Partin A.W., DeWeese T.L., Walsh P.C.// Long term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.//J. Urol., 1998, v 159−1- p. 173−177, Discussion 177−178.
39. Cadeddu J.A., Stoianovici D., Kavoussi L.R.// Robotics in urologic surgery.// Urol., 1997, v. 49- 4- p. 501:507.
40. Carter H.B., Partin A.W., Oesterling J. E // The use of PSA in the management of patients with prostate cancer, The J. Hopkins experience.// In Clin. Asp. Of prostate cancer, New York, 1989- p. 247−254.
41. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al.// Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease.// JAMA., 1992, v.267- p.2215−2220.
42. Carver B.S., Kattan M.W., Scardino P.T., Eastham J.A.// Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy.// BJU Int., 2005, v.95- 4(Mar.) — p.509−12.
43. Chatterjee В.//The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.//Mol Cell Biochem., 2003, — v.253−1-2 (Nov) — p.89−101. Review.
44. Cheng L., Paterson R.F., Beck S.D., Parks J.// Prostatic intraepithelial neoplasia: ah update.//Clin Prostate Cancer., 2004, v.3−1 (Jun) — p.26−30. Review.
45. Chodak G.W., Kranc D.M., Puy L.A., et al.// Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate.// J. Urol., 1992, v. 147- p.798−803.
46. Cooner W., Mosly B.R., Rutherford C.// Prostate cancer detection in a clinical urological practice by TRUS, DRE and PSA.// J. Urol., 1990, v. 143- p. 114 656.
47. Crane C.H., Rich T.A., Read P.W. et al.,// Pre-irradiation PSA predicts biochemical disease-free survival in patients treated with post-prostatectomy external beam irradiation.// Int. J. Radiation Oncol. Biol. Phys., 1997, v. 39- 3- p. 681−686.
48. Davidson D., Siroky M., Rudders R., et al.,// Prostatic intra-epithelial neoplasia is predictive of adenocarcinoma // Med. Pathol., 1994, v. 7- p.410.
49. Dillioglugil О., Leibamn B.D., Kattan M. W, Seal-Hawkins C., et al.,// Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer.// Urol., 1997, v 50−1- p. 93−99.
50. Dovey Z., Corbishley C.M., Kirby R.S.// Prostatic intraepithelial neoplasia: a risk factor for prostate cancer// Can. J. Urol., 2005, — v. 12 Suppl. 1 (Feb.) — p.49−52- discussion 99−100.
51. Epstein J.L. //Diagnostic criteria of limited adenocarcinoma of prostate on needle biopsy. Human Pathology., 1995, v. 26- p. 223−9.
52. Epstein J.L., Grignon DJ, Humphrey PA, et al. //Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia.// Am J Surg Pathol., 1995, v.19- p.873−86.
53. Feyaerts A., Delree A., Lorge F., et al.,// Recidive apres chirurgie radicale pour cancer prostatiques. Analyse des facteurs pronostiques, biologiques, et anatomopathologiques.// Acta Urol. Belg., 1997, v. 65−1- p. 11−18.
54. Fontana G., Governa N., Aime G., et al.,// Transurethral tissue vaporization: indications and limitations of the technique. Our experience in 105 cases.// Minerva Urol. Nefrol., 1997, v 49- 3- p. 173−177.
55. Fowler J.E. Jr., Pandey P., Bigler S.A., Yee D.T., Kolski J.M.,// Trends in diagnosis of stage Tla-b prostate cancer. Comment in: J. Urol. 1997- V158-N 5-P 1859:1860//J. Urol., 1997, v. 158−5- p 1849−1852.
56. Gaeta J.F., Asirwatham J.E., Miller G., Murphy G.P. //Histologic grading of primary prostatic cancer: a new approach to an old problem.//J Urol., 1980, v.123−5 (May) — p.689−93.
57. Gleason D.F. Classification of prostatic carcinomas // Cancer Chemother. Rep., 1966, v.50- p. 125−128.
58. Gleason D.F., Mellinger G.T. and the Veterans Administration Cooperative Urological Recearch Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging // J.Urol., 1974, v. Ill-p. 58−64.
59. Gleason D.F.//Histologie grading of prostate cancer: a perspective.// Human Pathology, 1992, v.23- p.273−9.
60. Goeman L., Joniau S., Ponette D. et al.// Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?//Prostate Cancer Prostatic Dis., 2003, v.6−4- p. 305−10.
61. Graves H.C.B., Sensbaugh G.F., Bleke R.T. //Postcoital detection of nonspecific semen protein.// New Engl. J. Med., 1985- p. 312−338.
62. Gumus B.H., Nese N., Gunduz M.I., Kandiloglu A.R., Ceylan Y., Buyuksu C.//Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens.//Int Urol Nephrol., 2004, v.36−4- p. 549−53.
63. Gupta A., Aragaki C., Gotoh M., Masumori N., Ohshima S., Tsukamoto Т., Roehrborn C.G.//Relationship between prostate specific antigen and indexes of prostate volume in Japanese men.//J Urol., 2005, v. 173−2 (Feb) — p.503−6.
64. Habib F.K., Odoma S., Busuttil A., et al. //Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor.// Cancer Res., 1986, v. 47- p.2351−6.
65. Halushka M.K., Kahane H., Epstein J.L.//Negative 34betaE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases.// Hum Pathol., 2004, v.35−1 (Jan) — p.43−6.
66. Helpap B.//Future directions in research of prostate carcinoma.//Pathol Res Pract., 1993, v. 189−5 (Jun) — p.497−509. Review.
67. Herawi M., Parwani A.V., Irie J., Epstein J.L.// Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion.//Am J Surg Pathol., 2005, 29−7 (Jul) — p.874−80.
68. Homma Y., Akaza H., Okada K., et al.,// Pre-operative endocrine therapy for clinical stage A2, B, and С prostate cancer: an interim report on short-term effects./ prostate cancer study group//Int. J. Urol., 1997, v. 4- 2- p. l44−151.
69. Hsieh T.F., Chang C.H., Chen W.C., Chou C.L., Chen C.C., Wu H.C.// Correlation of Gleason scores between needle-core biopsy and radical prostatectomy specimens in patients with prostate cancer.// J Chin Med Assoc., 2005, v.68−4(Apr) — p. 167−71.
70. Humphrey P. A.// Gleason grading and prognostic factors in carcinoma of the prostate.//Mod Pathol., 2004, v.17−3 (Mar) — p.292−306.
71. Kabalin J.N., Bite G., Doll S., //Neodymium:YAG laser coagulation prostatectomy: 3 years of experience with 227 patients.// J. Urol., 1996, v. 1551 (Jan.) — p. 181−185.
72. Kallakury B.V., Sheehan C.E., Ambros R.A., Fisher H.A., Kaufman R.P.Jr., Ross J.S. //The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.//Cancer (Phila.), 1997, v.80- p.753−763.
73. Keetch D.W., Humphreg P., Stahl K., et al.,// Morphometry analysis and clinical follow up of isolated prostatic intra-epithelial neoplasia in needle biopsy of the prostate //J. Urol., 1995, v. 154- p.347−351.
74. Keshgegian A.A., Johnston E., Cnaan A.//Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma.// Am J Clin Pathol., 1998, v. 110−4- p.443−9.
75. Keyser D., Kupelian P.A., Zippe C.D., et al.// Stage Tl-2 prostate cancer with pretreatment prostate specific antigen level 10 ng/ml: radiation therapy or surgery?!// Int. J. Radiat. Oncol. Biol. Phys., 1997, v. 38- 4- p. 723−729.
76. Kim H.L., Yang X.J.//Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen// Inter. Braz. J. Urol., 2002, v. 28−5 (sept.- oct.) — p. 413−417.
77. Kolaf Z., Murray P.G., Scott K., Harrison A., Vojtcsek B. and Dusek J.//Relation of Bcl-2 expression to androgen receptor, p21WAFl/CIPl, and cyclin D1 status in prostate cancer//J Clin Pathol: Mol Pathol, 2000, v.53- p. 15−18.
78. Kozuka Y., Imai H., Yamanaka M. et al.// Histopathological features of prostate cancer//Nippon Rinsho., 2005, v. 63−2 (Feb.) — p.231−6. Review. Japanese.
79. Krajewska M., Krajewski S., Epstein J.L. et.al.,//Immunohistochemical analysis of bcl2, Bax, bclx and mcl-1 expression in prostate cancers.//Am. J. Pathol., 1996, v. 148−5 (May) — p. 1567−76.
80. Kruslin В., Tomas D., Cupic H., Belicza M.//Periacinar refraction clefting in prostatic needle core biopsies: an important diagnostic criterion or a simple artefact?// Virch. Archive, 2003, v.443- p.524−7.
81. Kwak C., Ku J.H., Kim Т., Park D.W., Choi K.Y., Lee E., Lee S.E., Lee C.//Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer.// Urology, 2003, v.62−5 (Nov) — p. 854−9.
82. Lelja H. //A kallikrein-like serine protease in prostatic fluid leaves the predominant seminal vesicle proteins. //J. Clin. Invest., 1985, v.76- p. 18 992 006.
83. Leroy X., Aubert S., Villers A., Ballereau C. et al.//Minimal focus of adenocarcinoma on prostate biopsy: clinicopathological correlations// J.Clin.Pathology, 2003, v.56- p.230−232.
84. Li T.S., Belling C.G. //Isolation and characterization of two specific antigen of human seminal plasma. // Fertie Sterie, 1973, v. 21- p. 174−180.
85. Light D.J., Lange P.H., Ercole C.J., et al.// Serum PSA and the utility of isotopic bone scan (BOS) in the monitoring of patients with carcinoma of the prostate// Pros. Amer. Ass. Clin. Oncol., 1988.
86. Linton H.J., Marks L.S., Millar L. S., et.al.,// Benign Prostate-specific Antigen (BPSA) in Serum Is Increased in Benign Prostate Disease// Clinical Chemistry, 2003, v.49- p.253−259.
87. Lujan Galan M., Paez Borda A., Romero Cajigal I., Gomez de Vicente J.M., Berenguer Sanchez A.// Clinical significance of prostatic intraepithelial neoplasia//Arch Esp Urol., 2000, 53- 3 (Apr) — p.227−9.
88. Ma W.X., Li W.//Immunohistochemical detection of prostate carcinoma//Zhonghua Bing Li Xue Za Zhi., 1989 18- 1 (Mar) — p. 37−9. Chinese.
89. Maetman T.J. // The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate.// J. Urol., 1989, v. 141- p. 1378.
90. Marchal E.C., Caballero A.J., Padilla L.M., Villar A.E., Villalobos J.// Primary transitional cell carcinoma of the prostate. An infrequent tumor.// Actas Urologicas Espanolas., 1997, v. 21- 9- p. 926−930.
91. Marija Drobnjak, Iman Osman, Howard I. Scher, Melissa Fazzari and Carlos Cordon-Cardo//Overexpression of Cyclin D1 Is Associated with Metastatic prostate Cancer to Bone//Clinical Cancer Research, 2000, v. 6, (May) — p. 18 911 895.
92. McDonnell T.J., Navone N.M., Troncoso P., et al. //Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer.// J Urol., 1997, v. 157−2- p.569−74.
93. McNeal J.E., Bostwick D.G.,//Intraductal dysplasia: a premalignant lesion of the prostate.//Hum Pathol., 1986, v. 17−1 (Jan.) — p.64−71.
94. Miele ME.//Percent free PSA as an additional measure in a prostate cancer screen.//Clin Lab Sci., 2001, v. 14−2 (Spring) — p. 102−7.
95. Minardi D., Galosi A., Dell’Atti L. et al// Production of Serum-free and Total Prostate-specific Antigen Due to Prostatic Intraepithelial Neoplasia// Scand. J. of Urol and Nephr., 2002, v. 36- 5 (Nov. 30) — p.323 329.
96. Molinie V.// Prostatic intraepithelial neoplasia//Ann Pathol., 2001, v.21−3 (Jun) — p.245−54.
97. Montironi R., Hamilton P.W., Scarpelli M., et al.//Subtle morphological and molecular changes in normal-looking epithelium in prostates with prostatic intraepithelial neoplasia or cancer.//Eur Urol., 1999, v.35- p.468−73.
98. Morgan W.R., Zincke A., Rainvater L.// Prostate specific antigen after radical prostatectomy for adenocarcinoma of the prostate: Impact of adjuvant treatment (hormonal and radiation.//J. Urol., 1991, v. 145- p. 319.
99. Morote J., Lopez M., Encabo G., de Torres I.M.//Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen.//Eur Urol., 2000, v.37−5 (May) — p.537−40.
100. Morris M.M., Dallow K.C., Zietman A.L., et al.,// Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.// Int. J. Radiat. Oncol. Biol. Phys., 1997, v 38- 4- p. 731−736.
101. Mostofi F.K., Sesterhtnn I.A., Davis C.J.//World Health Organization, Histological typing of prostate tumuors.// 2002 (Jan.).
102. Mostofi F.K.//Grading of prostatic carcinoma.//Cancer Chemother Rep., 1975, v.59−1 (Jan-Feb) — p. l 11−7.
103. Moul J.W. //Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. //Eur Urol., 1999, v.35(5−6) — p.399−407.
104. Murphy W.M.//Prognostic factors in the pathological assessment of prostate cancer // Hum.Pathol., 1998, v. 29- p. 427−430.
105. Murphy W.M.//The current status of the pathology of prostate cancer // Cancer Control., 1998, v. 5- p. 500−506.
106. Myrtle J.F., Klinley P.G., Ivor L.P., et al.// Clinically utility of PSA in the management of prostatic cancer.//In. Advances in cancer diagnostics. San Diego. CA., 1986.
107. Myrtle J.F.// Normal levels of prostate specific antigen in clinical aspects of prostatic cancer., IN. Catalona D (sd) New York// 1989- p. 183−189.
108. Naz S., Ahmad S., Ghafoor F., Butt N.S., Akhtar M.W.//Free and total prostate specific antigen in benign prostate hyperplasia and prostate cancer.// J Coll Physicians Surg Рак., 2004, v. 14−2 (Feb.) — p.69−71.
109. Oesteling J.E., // Using PSA to eliminate the staging radionuclide bone scan: significant economic implications.// Urol. Clin. North Amer., 1994, v.20- 4- p. 705−726.
110. Ohori M., Egma S., Wheebr T.M.// Nodules resembling nodular hyperplasia in the peripheral zone of the prostate gland.// J. Urol. Path., 1994, v.2- p.223−233.
111. Oliai B.R., Kahane H., Epstein J.L.// Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.// Am J Surg Pathol., 2002, v.26−9 (Sep) — p. l 151−60.
112. Oliver R.T., Williams G., Paris A.M., Blandy J.P.// Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone- resistant prostate cancer.// Urology, 1997, v. 49−1- p. 79−82. 197.
113. Papsidro L.D., Wang M.C. et al., // A PSA in sera of prostatic cancer patients. // Cancer, 1980, v.40-p. 2428.
114. Planz В., Szska P., Valdor M., et al.,// Detection of circulating prostatic cells during radical prostatectomy.// Urol. Research, 1997, v. 25- 6- p. 385−389.
115. Polito M., Minardi D., Recchioni A., et al.// Serum markers for monitoring of prostatic carcinoma.// Prostate, 1997, v. 33- 3- p. 208−216.
116. Pound C.R., Walsh P.C., Epstein J. I., et al.// Radical prostatectomy as treatment for prostate specific antigen detected stage TIC prostate cancer.// world J. Urology, 1997, v. 15- 6- p. 373−377.
117. Prestigiacomo A. F, Stamey T.A.-// A comparison of 4 ultra sensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy.//J. Urol., 1994, v. 152- p.1515−1519.
118. Rubenstein J.H., Katin M.J., Mangano M.M., et al.,// Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy.// Am. J. Clin. Oncol., 1997, v. 20- 4- p. 376 380.
119. Ruij’ter E., van De Kaa C., Miller G. et al. //Molecular genetics and epidemiology of prostate carcinoma// Endocrin. Rev., 1999, v.20- p. 22−45.
120. Shabbir M., Mumtaz F.H.// Benign prostatic hyperplasia.//.! R Soc Health, 2004, v. 124−5 (Sep.) — p.222−7. Review.
121. Shelfo S.W., Obek C., Soloway M.S.// Update on bladder neck preservation during radical retro pubic prostatectomy: impact on pathologic outcome, anastigmatic structures, and continence.// Urology, 1998, v. 51−1- p.73−78.
122. Sinha B.K., Yamazaki H., Eliot H.M., Schneider E., Borner M.M., O’Connor P.M.//Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells.// Biochim Biophys Acta., 1995, v. 1270−1- p. 12−8.
123. Small E.J. //Prostate cancer// Curr Opin. Oncol., 1997, v.9- 3- p.277−286.
124. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., Downs J.//The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years 111 J Urol., 2004, v. 172(4 Pt 1) (Oct) — p. 1297−301.
125. Stamey T.A., Prestigiacomo A. F, Chen Z.^/Standardization of immunoassays for PSA: a different view based on experimental observations.//Cancer, 1994, v. 74- p. l662−1666.
126. Stamey T.A., Yang N., Hay A.R. et al.,// Prostate specific antigen as aserum marker for adenocarcinoma of the prostate.// N Engl. J. Med., 1987, v. 317- p. 909−916.
127. Strobel S., Smith K., Wolfert R., Rittenhouse H.-//Role of free PSA discoedance across commercial PSA assays.//Clin. Chem., 1996, v.42- p.645−647.
128. Theodorescu D., Broder S.R., Boyd J.C., Mills S.E., Frierson H.F.Jr.//p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.//J Urol., 1997, v. 158−1- p. 131 -7.
129. Thorson P., Humphrey P.A.//Minimal adenocarcinoma in prostate needle biopsy tissue.// Am J Clin Pathol., 2000, v. 114−6 (Dec) — p.896−909.
130. Thorson P., Vollmer R.T., Arcangeli C. et al.//Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up//Mod.Pathology, 1998, v. l 1, p. 543−51.
131. Tunn U.M.,// Neo-adjuvant hormonal therapy of prostate cancer.// Urol. Res., 1997, v.25-Suppl 2- p. 557−62.
132. Vessella R.L., Lange P.H.-//Issue in the assessment of PSA immunoassays.// Urol. Clin North Am., 1993, v.20- p.607−619.
133. Vessella R.L.// Trends in immunoassays of PSA- serum complexes and ultra-sensitivity.// Clin. Chem., 1993, v.39- p.2035−2037.
134. Weber J.P., Oesterling J.E. Peters C.A.// The influence of reversible androgen deprivention on serum prostate specific antigen levels in men with BPH.// J. Urol., 1989, v.141- p. 987.
135. Wener M.H., Daum P.R., Brawer M.K.//Variation in measurement of PSA: importance of method and lot variability.//Clin. Chem., 1995, v.41- p. 17 301 737.
136. Wildschutz Т., Janssen Т., Schulman С.// Predictive value of the serum PSA level in patients having undergone neo-adjuvant hormone treatment before radical prostatectomy.// Acta Urologica Belgica, 1995, v. 63−1- p. 79−82.
137. Wilson T.M., Blute M.L. Oesterling J.E. et al., // Evaluation of the suspicious prostate: PSA ultrasonic and digital guided biopsy- what markers a difference (abs 6210)// J. Urol., 1991, v. 145- p.568.
138. Wirth M., Otto Т., Rubben H. Prostatakarzinom // Diagnostische und therapeutische Standards in der Urologischen Onkologie / Hrsg. im Auftr.der Deutschen Krebsgesellschaft. von L. Weisbach und K. Miller, 1998- s.92−126.
139. Xiong Y., Zhang H., Beach D.// D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA.//Cell, 1992, v.71- p.505−14.
140. Yeniyol C.O., Bozkaya G., Cavusoglu A., Arslan M., Karaca В., Ayder A.R.// The relation of prostate biopsy results and ratio of free to total PSA in patients with a total PSA between 4−20 ng/ml //Int Urol Nephrol., 2001, v.33−3- p.503−6.
141. Yu H., Diamandis E.P., Nam R., Trachtenberg J.// Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 mic.gr./L//J. Urol., 1997,. V. 157- 3 (Mar.) — p. 913−918.
142. Zaviacic.M.//Prostate specific antigen and history of its disco very.//Bratislavske Lekarske Listy., 1997, v. 98 -12- p. 659−662.